Prism Medico & Pharmacy Ltd Directors Report.

Your Directors are pleased to present the 18th Annual Report covering the operational and financial performance of your Company along with the Audited Financial Statements for the financial year ended March 31, 2020.

1 FINANCIALHIGHLIGHTS:

The Standalone Financial results are briefly indicated below:

Particulars 2019-20 2018-19
Revenue from Operations 26,89,01,792 36,30,61,615
Other Income 0 21,87,442
Profit/loss before Depreciation, Finance Costs, Exceptional items and Tax Expense (502496) 3201520
Less: Depreciation/ Amortisation/ Impairment 1,76,180 266,990
Profit /loss before Finance Costs, Exceptional items and Tax Expense (678676) 29,34,530
Less: Finance Costs 2494 2,264
Profit /loss before Exceptional items and Tax Expense (6,81,170) 29,32,266
Add/(less): Exceptional items - -
Profit /loss before Tax Expense (6,81,170) 29,32,266
Less: Tax Expense
• Current Tax 0 5,64,168
• Deferred Tax 1,78,623 6,31,785
• MAT Credit Entitlement 0 6,94,471
Profit /loss for the year (5,02,546) 36,94,354

2. REVIEW OF OPERATIONS

Your Company has prepared the Financial Statements for the financial year ended March 31, 2020 in terms of Sections 129,133 and Schedule III of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. The Company has incurred loss of Rs. 502546/- during the financial year under review. Your Directors expect to achieve better performance in the future taking maximum efforts to control the costs and optimize the results in the coming years.

3. CHANGE IN NATURE OFBUSINESS

There is no change in the nature of Business during the financial year 2019-20.

4. TRANSFER TORESERVES

The company has transferred Rs. 5,02,546 being the loss for the current financial year to Reserves & Surplus.

5. DIVIDEND

The company does not recommend any dividend due to losses incurred during the year.

6. SHARE CAPITAL

The Authorized Share Capital of the Company as on March 31, 2020 stands at Rs. 10 Crore divided into 1,00,00,000 equity shares of Rs. 10/- each. The Issued Share Capital of the Company remains at Rs. 6,06,34,280

divided into 60,63,428 equity shares of Rs. 10/- each and the Subscribed and Paid-up Share Capital is Rs. 6,06,34,280 divided into 60,63,428 equity shares of Rs. 10/- each, fully paid-up. There was no change in the share capital of the Company during the financial year 2019-20.

7. MATERIAL CHANGES AND COMMITMENTS AFFECTING FINANCIA POSITION

BETWEEN END OF THE FINANCIAL YEAR AND THE DATE OF THISREPORT

Subsequent to the end of the financial year on March 31, 2020 till date, there has been no material change and / or commitment which may affect the financial position of the Company.

8. ADOPTION OF INDIAN ACCOUNTING STANDARD (INDAS)

The Ministry of Corporate Affairs vide notification dated 16 February 2015 made it mandatory in a phased manner for adoption and applicability of Indian Accounting Standards (Ind AS) for companies other than Banking, Insurance and Non-Banking Finance Companies. Rule 4 of the Companies (Indian Accounting Standards) Rules 2015 specifies the classes of companies which shall comply with the Ind AS in preparation of the financial statements. In accordance with clause (iii) of sub rule (1) of the Rule 4 of the Companies (Indian Accounting Standards) Rules 2015, the compliance of Indian Accounting Standards was applicable and mandatory to the company for the accounting period beginning from 1 April 2017. The financial statements for the year under review have been prepared in accordance with the IndAS.

9. DEPOSITS

During the period under review the Company has neither accepted nor invited any Public deposits. Hence the provisions of Section 76 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014 are not applicable.

10. CORPORATE SOCIAL RESPONSIBILITY(CSR)

The provisions of Section 135 of the Companies Act relating to Corporate Social Responsibility are not applicable as the Company is having Net worth less than rupees Five Hundred Crore, Turnover less than rupees One Thousand Crore and Net Profit less than rupees Five Crore.

11. RELATED PARTY TRANSACTIONS

During the financial year ended March 31, 2020, all transactions with the Related Parties as defined under the Companies Act, 2013 read with Rules framed thereunder were in the ordinary course of business and at arms length basis.

Your Company has formulated a Policy on Related Party Transactions and the said Policy has been uploaded on the website of the Company atwww.prismmedico.com.

All Related Party Transactions of your Company had prior approval of the Audit Committee and the Board of Directors, as required under the Listing Regulations. Subsequently, the Audit Committee and the Board have reviewed the Related Party Transactions on a quarterly basis.

Form AOC-2 containing particulars of contracts or arrangements entered into by the Company with related parties referred in Section 188(1) of the Companies Act, 2013 is attached as Annexure - A. Details of related party transactions and related disclosures are given in the notes to the financial statements.

12. NUMBER OFMEETINGS:

The Board has met 9 (Nine) times during the financial year, the details of which are as under:

25th April, 2019, 30thMay, 2019, 17th June 2019, 13thAugust 2019, 30th August 2019,

14th October, 2019, 30th December 2019, 27th January 2020 and 30th January 2020.

Meeting of the Board of Directors which was to be held on 29/05/2019 was adjourned and was held on 30/05/2019. Also, The intervening gap between any two meetings did not exceed 120 days as prescribed by the Companies Act, 2013.

Details of Attendance of Directors:

Name of the Director Number of Meetings entitled to attend Number of Meetings attended
1. Mr. Jasjot Singh 2 2
2. Mr. Gursimran Singh 5 5
3. Ms. Simmi Chhabra 5 5
4. Ms. Charu Pareek 9 7
5. Mr. Sehejbir Singh Bhatia 9 9
6. Mr. Rishi Pal Panwar 9 9
7. Mr. Mr. Sudhanshu Srivastav 4 4
8. Mr. Jimit Jitendra Trivedi 4 4

Details of number of meeting attended by Directors:

Date of Meeting Number of Directors entitled to attend Number of Directors attended
1. 25/04/2019 6 6
2. 30/05/2019 6 5
3. 17/06/2019 5 4
4. 13/08/2019 5 5
5. 30/08/2019 5 5
6. 14/10/2019 5 5
7. 30/12/2019 5 5
8. 27/01/2020 5 5
9 30/01/2020 5 5

13. COMPOSITION OF COMMITTEES

As per the applicable provisions of the Companies Act,2013 & Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2018, three Committees have been constituted in the company which are as follows:-

a) Audit Committee

The Board of Directors of your Company has duly constituted an Audit Committee in compliance with the provisions of Section 177 of the Companies Act, 2013, the Rules framed thereunder read with Regulation 18 of the Listing Regulations. The terms of reference of the Audit Committee has been duly approved by the Board of Directors. The recommendations made by the Audit Committee are accepted by your Board.

The committee met 5 (Five) times during the F.Y.2019-20:

Date of Meeting Number of Members entitled to attend Number of Members attended
1 25/04/2019 3 3
2 29/05/2019 3 3
3 13/08/2019 3 3
4 14/10/2019 3 3
5 30/01/2020 3 3

Details of Composition and Attendance of Members of the Audit Committee as on 31.03.2020 is as below:

S.No. Name of the Director Category/ Designation Number of Committee Meetings entitled to attend Number of Committee Meetings attended
1. Mr. Sudhanshu Srivastav (w.e.f. 14t/10/2019) Member & Executive Director 2 2
2. Ms. Charu Pareek Member & Independent NonExecutive Director 5 5
3. Mr. Rishi Pal Panwar Member & Independent NonExecutive Director 5 5
4. Ms. Simmi Chhabra (upto 05/10/2019) Member & Independent NonExecutive Director 3 3

Mr. Sudhanshu Srivastav was appointed as the member of Audit Committee on 14th October 2019 due to resignation of Ms. Simmi Chhabra as the member of the Audit Committee on 05th October 2019.

b) Nomination & Remuneration Committee The committee met 3 (Three) times during the F.Y. 2019-20:

S.No. Date of Meeting Number of Members entitled to attend Number of Members attended
1 17/06/2019 3 3
2 14/10/2019 3 3
3 30/12/2019 3 3

Details of Composition and Attendance of Members of the Nomination & Remuneration Committee as on 31.03.2020 is as below:

Name of the Director Category/ Designation Number of Committee Meetings entitled to attend Number of Committee Meetings attended
1. Ms. Charu Pareek Member & Independent NonExecutive Director 3 3
2. Mr. Rishi Pal Panwar Member & Independent NonExecutive Director 3 3
3. Mr. Sudhanshu Srivastav (w.e.f. 14/010/2019) Member & Executive Director 2 2
4. Ms. Simmi Chhabra (upto 05/10/2019) Member & Independent NonExecutive Director 1 1

Mr. Sudhanshu Srivastav was appointed as the member of Nomination & Remuneration Committee on 14th October 2019 due to resignation of Ms. Simmi Chhabra as the member of the Nomination & Remuneration Committee on 05th October 2019.

c) Stakeholder Grievance Committee

The Board of Directors of the Company constituted a Stakeholders Relationship Committee of the Board in terms of the requirements of Section 178 of the Companies Act, 2013 and Rules framed

thereunder read with Regulation 20 of the Listing Regulations.

The committee met Once during the F.Y 2019-20:

S.No. Date of Meeting Number of Members entitled to attend Number of Members attended
1 20.03.2020 3 3

Details of Composition and Attendance of Members of the Stakeholder Grievance Committee as on 31.03.2020 is as below:

S.No. Name of the Director Category/ Designation Number of Committee Meetings entitled to attend Number of Committee Meetings attended
1. Mr. Rishi Pal Panwar Member & Independent NonExecutive Director 1 1
2. Ms. Charu Pareek Member & Independent NonExecutive Director 1 1
3. Mr. Sudhanshu Srivastav (w.e.f. 14/10/2019) Member & Executive Director 1 1
4. Ms. Simmi Chhabra (upto 05/10/2019) Member & Independent NonExecutive Director N.A. N.A,

Mr. Sudhanshu Srivastav was appointed as the member of Stakeholder Grievance Committee on 14th October 2019 due to resignation of Ms. Simmi Chhabra as the member of the Stakeholder Grievance Committee on 05th October 2019.

14. DIRECTORS AND KEY MANAGERIALPERSONNEL:

A. REAPPOINTMENT OFDIRECTOR:

Mr. Sudhanshu Srivastav who retires by rotation being eligible offers himself for re- appointment at the ensuing Annual General meeting.

B. INDEPENDENTDIRECTORS:

The Company has received declaration from all the Independent Directors of the Company confirming that they meet with criteria of Independence as prescribed under sub-section (6) of section 149 of the Companies Act, 2013 and under clause 49 of the Listing Agreements with the Stock Exchanges.

The Independent Directors have met once during the financial year 2019-20 on 20th March 2020 without the attendance of non-independent directors and members of the Management.

None of the Directors of your Company is disqualified under Section 162 (2) of the Companies Act, 2013. As required by law, this position is also reflected in the Auditors Report.

C. APPOINTMENT OFDIRECTOR:

During the year under review, following persons were appointed as Directors of the company:

i. Mr. Sehejbir Singh Bhatia was appointed as Additional Director on 17/06/2019 and regularized at the Annual General Meeting held on 30th September 2019.

ii. Mr. Sudhanshu Srivastav was appointed as Additional Director on 14/10/2019.

iii. Mr. Jimit Jitendra Trivedi was appointed as Additional Director on 14/10/2019.

D. CESSATION OF DIRECTOR:

During the year under review, following Directors resigned from the directorship of the company:

i. Mr. Jasjot Singh resigned with effect from 08/06/2019

ii. Mr. Sehejbir Singh Bhatia resigned with effect from 08/06/2019

iii. Mr. Gursimran Singh resigned with effect from 05/10/2019

iv. Ms. Simmi Chhabra resigned with effect from 05/10/2019

E. KEY MANAGERIALPERSONNEL:

During the year under review, Ms. Swati Pandey (ACS- 54947) who was appointed as Company Secretary with effect from 11.12.2018, served her services till 31st December, 2019. As on 31/03/2020 there was no Company Secretary appointed in the company. Further, Mr. Sameer Gupta (ACS- 59256) was appointed as Company Secretary on 08thJune 2020.

Therefore, as on 31st March, 2020 following persons have been designated as Key Managerial Personnel of the Company pursuant to Section 2(51) and Section 203 of the Act, read with the Rules framed thereunder.

(i) Mr. Gursimran Singh—Chief Financial Officer.

15. SUBSIDIARIES/ ASSOCIATES/IOINT VENTURES

During the year under review, The Company had no Joint ventures and Associate Companies as per the provisions of Companies Act, during the financial year ended on 31st March, 2020.

Further, the company had one wholly owned subsidiary i.e. Healthy Biosciences Private Limited till 27th January, 2020, as the company had sold its shareholding in the M/s Healthy Biosciences Private Limited as on said date. Also there was no loss/profit on the transfer of shares. Therefore, as on 31st March, 2020 company has no subsidiary as per the provisions of Companies Act,2013.

Pursuant to the provisions of Section 129(3) of the Companies Act, 2013 read with Rule 5 of the Companies (Accounts) Rules, 2014, a statement containing the salient features of Financial Statements of the aforesaid Subsidiaries has been provided in Form AOC-1 and forms part of this Annual Report and marked as "Annexure B".

16. DIRECTORS RESPONSIBILITYSTATEMENT:

Pursuant to the requirement under Section 134 (5) of the Companies Act, 2013, with respect to Directors Responsibilities Statement, it is hereby confirmed:

a) That in the preparation of the annual accounts for the financial year ended 31st March, 2020 the applicable Ind accounting standards had been followed along with proper explanation relating to material departures.

b) that the Directors has selected such accounting policies and applied them consistently and made judgments and estimates that were reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for the year review.

c) that the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities, and,

d) The Directors had prepared the accounts for the financial year ended 31st March, 2020 on a going

concern basis.

e) The Directors had laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively.

f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

17. EXTRACT OF ANNUALRETURN:

The details forming part of the extract of the Annual Return in form MGT-9 is annexed herewith as Annexure to the Board Report and marked as Annexure C and the same is available on the website of the Company at www.prismmedico.com

18. MANAGEMENT DISCUSSION ANALYSIS REPORT:

The details forming part of Management Discussion and Analysis Report is annexed herewith as Annexure to the Board Report. ANNEXURE D.

19 PARTICULARS OF EMPLOYEES

Disclosure required under Section 197 of the Companies Act, 2013 read with rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 as amended up to date is not applicable since your Company has no such employees. However, disclosure is annexed as Annexure E

20. SECRETARIAL AUDITOR AND SECRETARIAL AUDIT REPORT

As required under section 204 (1) of the Companies Act, 2013 and Rules made there under the Company has appointed M/s. M.R. Chechi & Associates, Company Secretaries, Chandigarh as Secretarial Auditor to conduct the Secretarial Audit of the Company for the financial Year 2019-20. The Secretarial Audit Report for the financial year ended 31st March 2020 is attached as Annexure F to the Boards Report. This report contains observation as mentioned below alongwith the replies:

1. During the year under review the company did not pubiish the notice of Board of Directors meeting held on 30th January, 2020 where financial results for the quarter ended 31st December, 2019 were discussed and approved.

Reply: The company had given the Notice for publication in the newspaper to the Advertisement agency but due to lack of communication and confirmation for publication, the same could not be done.

21. AUDITORS & AUDITORS REPORT:

In terms of the provisions of Section 139 of the Companies Act, 2013 read with provisions of the Companies (Audit and Auditors) Rules, 2014 as amended from time to time, M/s. Harjeet Parvesh& Co., Chartered Accountants (Firm Registration No. 017437N) (Peer Review Certificate No. 011668) who were appointed as the Auditors of the Company for a consecutive period of 5 (five) years from conclusion of the 15thAGM held in the year 2017 until conclusion of the 20thAGM of the Company scheduled to be held in the year 2022 continue to be statutory auditors of the company.

The Report given by the Auditors on the financial statement of the Company forms part of this Report as Annexure "G".

There has been no qualification, reservation, adverse remark or disclaimer given by the Auditors in their Report. During the year under review, the Auditors had not reported any matter under Section 143 (12) of the Companies Act, 2013.

22. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS ANDOUTGO

Information in accordance with the provisions of Section 134 (3)(m) of the Act read with the Companies (Disclosure of Particulars in the Report of Board of Directors) Rules, 1988, regarding Conservation of Energy, Technology Absorption and Foreign Exchange Earnings and Outgo is not applicable on the Company.

23. MECHANISM FOR EVALUATION OF BOARD

Pursuant to the provisions of the Companies Act, 2013 and regulation 17(10) of SEBI (LODR) Regulation 2015, a structured procedure was adopted after taking into consideration of the various aspects of the Boards functioning composition of the Board and its committees, execution and performance of specific duties, obligations and governance.

The performance evaluation of the independent Directors was completed in time. The performance evaluation of the Chairman and the Non-independent Directors was carried out by the Independent Directors. The Board of Directors expresses their satisfaction with the evaluation process.

The performance of each committee has been evaluated by its members and found to be highly satisfactory.

On the basis of this exercise, the Board has decided that all Independent Directors should continue to be on the Board.

24. IMPLEMENTATION OF RISK MANAGEMENTPOLICY:

The Company has formulated a policy and process for Risk Management. The Company has set up a core group of leadership team, which identifies, assesses the risks and the trends, exposure and potential impact analysis at different level and lays down the procedure for minimization of risks. Risk Management forms an integral part of Management policy and is an ongoing process integrated with the operations.

The Company has identified various strategic, operational and financial risks which may impact Company adversely. However management believes that the mitigation plans for identified risks are in place and may not threaten the existence of the Company.

25. PARTICULARS OF LOANS. GUARANTEES ORINVESTMENTS:

The Company has not given any loan/guarantee or provided any security during the year under review under the provisions of section 186 of the Companies Act, 2013.

26. WHISTLE BLOWER POLICY AND VIGILMECHANISM:

The Company has formulated and communicated the Whistle Blower Policy to all its directors and employees and the same is posted on the Companys Website www.prismmedico.com(http://prismmedico.com/policy-whit.pdf)

Your Company recognizes the value of transparency and accountability in its administrative and management practices. The Company promotes the ethical behavior in all its business activities. The Company has adopted the Whistle blower Policy and Vigil Mechanism in view to provide a mechanism for the Directors and employees of the Company to approach Audit Committee of the Company to report existing/probable violations of laws, rules, regulations or unethical conduct.

27. DISCLOSURES UNDER SEXUAL HARRASMENT OF WOMEN AT WORKPLACE f PREVENTION- PROHIBITION & REDRESSAL)ACT. 2013

The Company has zero tolerance for sexual harassment at workplace and has adopted a Policy on prevention, prohibition and redressal of sexual harassment at workplace in line with the provisions of The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules framed thereunder. Further, the Company has Internal Complaint Committees for various locations of the Company in compliance with the above mentioned Act and Rules. During the financial year 2019-20, no complaint has been received during the year under review.

28. STOCKEXCHANGES:

The Companys shares are listed on the following Stock Exchanges:

(i) Bombay Stock Exchange Limited (BSE Ltd.)

(ii) Metropolitan Stock Exchange of India (MSEI Ltd.)

29. LISTINGFEES:

The Annual Listing Fee for the financial year 2019-20 had been paid to those Stock Exchanges where the Companys shares are listed.

30. POSTALBALLOT:

The Company has conducted Postal Ballot during the year under review.

31. CORPORATEGOVERNANCE

As per Regulation 15(2) of SEBI (Listing Obligation and Disclosures requirement) Regulation, 2015, report on Corporate Governance is not applicable as the Company is not falling within the prescribed ambit as mentioned there in.

32. NOMINATION AND REMUNERATIONPOLICY

The appointment and remuneration of Directors is governed by the recommendation of Nomination and Remuneration Committee and then decided by the Board subject to approval of the shareholders. The Company had made a policy on it and the same is available on the website of the Company www.prismmedico.com.

The remuneration payable to the Directors is decided keeping into consideration long term goals of the Company apart from the individual performance expected from a director(s) in pursuit of the overall objectives of the Company.

The remuneration of Executive Director(s) including Managing Director(s) and Whole-time Director(s) is governed by the recommendation of Nomination and Remuneration Committee as per the criteria recommended by it and then approved by the Board subject to approval of the Shareholders.

The Non-executive Director(s) may be paid remuneration by way of commission either by way of monthly payments or specified percentage of net profits of the Company or partly by one way and partly by the other, as may be recommended by Nomination and Remuneration Committee and then decided by the Board subject to approval of the Shareholders.

In accordance with the provisions of the Articles of Association of the Company and the Companies Act, 2013, a sitting fees is paid to the Non-executive Directors of the Company who are not drawing any remuneration described hereinabove, for attending any meeting of the Board or of any Committee thereof.

The remuneration payable to Directors shall be governed by the ceiling limits specified under section 197 of the Companies Act, 2013. The remuneration policy for other senior management employees including key managerial personnel aims at attracting, retaining and motivating high caliber talent and ensures equity, fairness and consistency in rewarding the employees. The remuneration to management grade employees involves a blend of fixed and variable component with performance forming the core.

The components of total remuneration vary for different employee grades and are governed by industry practices, qualifications and experience of the employees, responsibilities handled by them, their potentials, etc.

33. INTERNAL AUDITORS & AUDITORS REPORT

As required under section 138 of the Companies Act, 2013 read with Rule 13 of the Companies (Accounts) Rules, 2014 made there under, the Company has appointed Internal Auditors to assess the risk management and to ensure that risk management processes are efficient, effective, secure and compliant. It is the basic check of internal control of the organization. An internal audit is an organizational move to check, ensure, monitor and analyze its own business operations in order to determine how well it conforms to a set of specific criteria.

34. ADEQUACY OF INTERNAL FINANCIALCONTROLS:

Your Companys internal financial control ensures that all assets of the Company are properly safeguarded and protected, proper prevention and detection of frauds and errors and all transactions are authorized, recorded and reported appropriately.

Your Company has an adequate system of internal financial controls commensurate with its size and scale of operations, procedures and policies, ensuring orderly and efficient conduct of its business, including adherence to the Companys policies, safeguarding of its assets, prevention and detection of frauds and errors, accuracy and completeness of accounting records, and timely preparation of reliable financial information.

35. DEMATERILISATION OF SHARES:

The Company has connectivity with NSDL & CDSL for dematerialization of its equity shares. The ISIN No. INE730E01016 has been allotted for the Company.

Further the Company does not have any Equity shares lying in the Suspense Account.

36. MAINTENANCE OF COST RECORDS

The Central Government has not prescribed the maintenance of cost records under Section 148(1) of the Companies Act, 2013 and Rules framed thereunder with respect to the Companys nature of business.

37. TRANSFER TO INVESTOR PROTECTION AND EDUCATION FUND (IEPF)

There are no unclaimed funds or shares to be deposited to the Investor Protection and Education Fund as on 31.03.2020.

38. TRADERELATIONS

The Board wishes to place on record its appreciation for the support and co-operation that the Company received from its suppliers, distributors, retailers and other associates. The Company has always looked upon them as partners in its progress and has happily shared with them rewards of growth. It will be Companys endeavour to build and nurture strong links based on mutuality, respect and co-operation with each other and consistent with customer interest.

39. COMPLIANCE WITH SECRETARIAL STANDARDS ON BOARD ANDGENERAL MEETINGS

During the year under review, the Company has duly complied with the applicable provisions of the Secretarial Standards on Meetings of the Board of Directors (SS-1) and General Meetings (SS-2) issued by The Institute of Company Secretaries of India(ICSI).

40. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS ORTRIBUNALS

There were no significant and material orders passed by the Regulators, Courts or Tribunals, during the year under review, which would impact the going concern status of the Company and its operations in future.

41. ACKNOWLEDGEMENTS

Your Directors would like to express their appreciation for assistance and co-operation received from the financial institutions, banks, Government authorities, customers, vendors and members during the year under review. Your Directors also wish to place on record their deep sense of appreciation for the committed services by the executives, staff and workers of the Company and the shareholders for their support and confidence reposed on the Company.

For And On Behalf Of The Board Of Directors For Prism Medico & Pharmacy Limited

Place: Mohali Sudhanshu Srivastav Jimit Jitendra Trivedi
Date:13/08/2020 Director Director
DIN - 08242441 DIN-08585697